About Mitchell R. Goldstein, MD
Dr. Goldstein attended the University of Miami’s Honor Program in Medical Education as an Isaac Bashevis Singer Scholar and completed a pediatric residency at the University of California, Los Angeles, and a Neonatal-Perinatal Medicine fellowship at the University of California, Irvine. Dr. Goldstein is board-certified in Pediatrics and Neonatal-Perinatal Medicine. He is a Professor of Pediatrics at Loma Linda University Children’s Hospital and the medical director of Neonatal ECMO.
Dr. Goldstein is Editor-in-Chief of Neonatology Today (NeonatologyToday.net), Chairman of Physicians Against Drugs Shortages (PADS), and Medical Director of the National Coalition for Infant Health (NCfIH). He is the past Chair of the AAP Multidisciplinary Action Group 2 Section Forum Management Committee and past president of the National Perinatal Association (NPA). Dr. Goldstein is the National AAP-appointed liaison between the Section on Advances in Therapeutics and Technology and the Section on Neonatal Perinatal Medicine. Dr. Goldstein is also the Chair-Elect for the AAP CA chapter 2 for 2024-2025.
Dr. Goldstein’s most important trait is his tireless devotion to patient access issues. He has been a vocal advocate for “right-sizing” technology. When his hospital, along with many others nationwide, was unable to purchase medical devices vital to patient care, Dr. Goldstein wrote to senators and members of Congress. He testified before a United States Senate Subcommittee of the Judiciary regarding the practices of Group Purchasing Organizations and the restriction of access to vital medical devices and pharmaceuticals. Dr. Goldstein’s vigilance in modifying these practices and improving patient access made the front page of the New York Times and was featured on 60 Minutes.
Dr. Goldstein advocates that improving the relationship between physicians and industry is crucial to providing exceptional care. He supports transparency, dialogue, and enhanced engagement with industry and insurers to ensure the development and availability of the most advanced pharmaceuticals and medical devices for at-risk pediatric patients.
https://myllu.llu.edu/utilities-fileManager/action:file/?item=%2FFacultyManagement%2F369%2FCV+MG+2025+June.docx
